213 related articles for article (PubMed ID: 29848379)
1. Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).
Martin-Rufino JD; Lozano FS; Redondo AM; Villaron EM; Rueda R; Fernandez-Samos R; Sanchez-Guijo F
Stem Cell Res Ther; 2018 May; 9(1):150. PubMed ID: 29848379
[TBL] [Abstract][Full Text] [Related]
2. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.
Gupta PK; Krishna M; Chullikana A; Desai S; Murugesan R; Dutta S; Sarkar U; Raju R; Dhar A; Parakh R; Jeyaseelan L; Viswanathan P; Vellotare PK; Seetharam RN; Thej C; Rengasamy M; Balasubramanian S; Majumdar AS
Stem Cells Transl Med; 2017 Mar; 6(3):689-699. PubMed ID: 28297569
[TBL] [Abstract][Full Text] [Related]
3. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease).
Cacione DG; do Carmo Novaes F; Moreno DH
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012794. PubMed ID: 30378681
[TBL] [Abstract][Full Text] [Related]
4. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease.
Saito Y; Sasaki K; Katsuda Y; Murohara T; Takeshita Y; Okazaki T; Arima K; Katsuki Y; Shintani S; Shimada T; Akashi H; Ikeda H; Imaizumi T
Circ J; 2007 Aug; 71(8):1187-92. PubMed ID: 17652879
[TBL] [Abstract][Full Text] [Related]
5. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model.
Kim SW; Han H; Chae GT; Lee SH; Bo S; Yoon JH; Lee YS; Lee KS; Park HK; Kang KS
Stem Cells; 2006 Jun; 24(6):1620-6. PubMed ID: 16497946
[TBL] [Abstract][Full Text] [Related]
6. Endovascular Recanalization of Thromboangiitis Obliterans (Buerger's Disease) in Twenty-Eight Consecutive Patients and Combined Antegrade-Retrograde Intervention in Eight Patients.
Firat A; Igus B
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):820-828. PubMed ID: 30834476
[TBL] [Abstract][Full Text] [Related]
7. Thromboangiitis obliterans (Buerger's disease).
Klein-Weigel PF; Richter JG
Vasa; 2014 Sep; 43(5):337-46. PubMed ID: 25147010
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans.
Durdu S; Akar AR; Arat M; Sancak T; Eren NT; Ozyurda U
J Vasc Surg; 2006 Oct; 44(4):732-9. PubMed ID: 16926085
[TBL] [Abstract][Full Text] [Related]
9. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease).
Lie JT
Acta Pathol Jpn; 1989 Mar; 39(3):153-8. PubMed ID: 2662703
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research.
Li MD; Wang YF; Yang MW; Hong FF; Yang SL
Curr Med Chem; 2020; 27(35):6057-6072. PubMed ID: 31419926
[TBL] [Abstract][Full Text] [Related]
11. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger's disease).
Park HS; Cho KH; Kim KL; Kim DK; Lee T
Vasc Med; 2013 Dec; 18(6):331-9. PubMed ID: 24292638
[TBL] [Abstract][Full Text] [Related]
12. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.
Kol A; Wood JA; Carrade Holt DD; Gillette JA; Bohannon-Worsley LK; Puchalski SM; Walker NJ; Clark KC; Watson JL; Borjesson DL
Stem Cell Res Ther; 2015 Apr; 6(1):73. PubMed ID: 25888916
[TBL] [Abstract][Full Text] [Related]
13. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
[TBL] [Abstract][Full Text] [Related]
14. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease).
Hooten WM; Bruns HK; Hays JT
Mayo Clin Proc; 1998 Jun; 73(6):529-32. PubMed ID: 9621859
[TBL] [Abstract][Full Text] [Related]
15. Visceral bed involvement in thromboangiitis obliterans: a systematic review.
Fakour F; Fazeli B
Vasc Health Risk Manag; 2019; 15():317-353. PubMed ID: 31616151
[TBL] [Abstract][Full Text] [Related]
16. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes.
Edo N; Miyai K; Ogata S; Nakanishi K; Hiroi S; Tominaga S; Aiko S; Kawai T
Cardiovasc Pathol; 2010; 19(1):59-62. PubMed ID: 19135391
[TBL] [Abstract][Full Text] [Related]
17. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
[TBL] [Abstract][Full Text] [Related]
18. Buerger's Disease in the Testicle: A Case of Testicular Thromboangiitis Obliterans.
Harwood EA; Blazek AJ; Radio SJ; Deibert CM
Cureus; 2023 Apr; 15(4):e37693. PubMed ID: 37206504
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells.
Motukuru V; Suresh KR; Vivekanand V; Raj S; Girija KR
J Vasc Surg; 2008 Dec; 48(6 Suppl):53S-60S; discussion 60S. PubMed ID: 19084740
[TBL] [Abstract][Full Text] [Related]
20. [Buerger's disease (thromboangiitis obliterans)].
Goiriz-Valdés R; Fernández-Herrera J
Actas Dermosifiliogr; 2005 Nov; 96(9):553-62. PubMed ID: 16476298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
